Rivernorth Capital Management LLC Makes New $2.99 Million Investment in Drugs Made In America Acquisition II Corp. $DMII

Rivernorth Capital Management LLC purchased a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 300,000 shares of the company’s stock, valued at approximately $2,991,000.

A number of other large investors also recently modified their holdings of the stock. Magnetar Financial LLC bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth approximately $26,730,000. Glazer Capital LLC bought a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at about $23,264,000. First Trust Capital Management L.P. bought a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $20,474,000. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Drugs Made In America Acquisition II during the first quarter worth $19,960,000. Finally, Hudson Bay Capital Management LP acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth $19,493,000.

Drugs Made In America Acquisition II Trading Up 0.1%

Shares of Drugs Made In America Acquisition II stock opened at $10.11 on Wednesday. The stock has a 50-day moving average price of $10.08. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.20.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on DMII. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.